Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 4/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | IL1B | P01584 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25155307 | 1.00 | KDM1A (0.44) | KDM1AHDAC8NR1D1ALOX5APPRMT5 | |
| SCHEMBL25156235 | 0.98 | KDM1A (0.41) | KDM1AHDAC8NR1D1ALOX5APGPR119 | |
| SCHEMBL30343995 | 0.98 | KDM1A (0.41) | KDM1AHDAC8NR1D1ALOX5APGPR119 | |
| SCHEMBL25156047 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL31360320 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL30344427 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL25156101 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL25155126 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL31360021 | 0.95 | HDAC8 (0.40) | KDM1AHDAC8NR1D1IL1BP2RX7 | |
| SCHEMBL31360159 | 0.89 | F2RL3 (0.39) | KDM1AHDAC8NR1D1ALOX5APGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | KDM1A 702/4885HDAC8 2441/4885NR1D1 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.